HY-2003 not checked
Sichuan Huiyu Pharmaceutical Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants received HY-2003 (10 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments. It is possible to explore the maximum number of administrations exceeding six treatment sessions.”In the company’s words, NCT06756490 on ClinicalTrials.gov
- Tested for
- Moderate or Severe Submental Fullness
- Main trialPhase 1
- “The main purpose of this study is to evaluate the safety of HY-2003 in subjects with moderate to severe submental fat accumulation at different doses and dosing frequencies in comparison with the positive control and placebo. The secondary objectives include: Evaluating the pharmacokinetic characteristics of HY-2003 after a single administration in humans and obtaining preliminary pharmacokinetic parameters; Evaluating the efficacy of HY-2003 under different doses and dosing frequencies, compared with the positive control and placebo, in the treatment of subjects with moderate to severe…”In the company’s words, NCT06756490 on ClinicalTrials.gov
Other drugs for Moderate or Severe Submental Fullness
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- TazemetostatEpizyme, Inc. · Phase 3
- EpcoritamabGenmab · Phase 3
- OdronextamabRegeneron · Phase 3
- SurovatamigAstraZeneca · Phase 3
- GolcadomideCelgene · Phase 3
Coming up1
- 6 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 6 Dec 2026 | A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026